関連文献

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

Eur J Clin Invest. 40(9): 790-796, 2010.PubMed

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Nephron Clin Pract. 112(3): c148-156, 2009.PubMed

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Diabetes Care. 32(9): 1684-1688, 2009.PubMed

Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.

Metabolism. 58(8): 1185-1190, 2009.PubMed

Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.

Nephrol Dial Transplant. 24(3): 788-800, 2009.PubMed

Renoprotective effect of telmisartan in patients with chronic kidney disease.

Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Clin Nephrol. 70(5): 385-392, 2008.PubMed

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

Diabetologia. 50(2): 490-492, 2007.PubMed

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Am J Med Sci. 333(6): 321-326, 2007.PubMed